Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Oxygen bath for donor livers may slash cancer return after transplant

NCT ID NCT06717919

Disease control Sponsor: Philipp Dutkowski Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether treating donor livers with a special oxygen-rich cold fluid (HOPE) before transplant can help prevent liver cancer from returning. About 220 adults with liver cancer waiting for a transplant will be randomly assigned to receive either a standard preserved liver or one treated with HOPE. Researchers will track cancer recurrence and survival for at least two years after transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult recipients (\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnetic resonance imaging or computer tomography of the liver or biopsy proven), * within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point of liver transplantation, * written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC Exclusion Criteria: * Donation after circulatory death (DCD) liver grafts * Combined liver transplants * Partial liver transplants * Combined or mixed hepatocellular cholangiocarcinoma (cHCC-CCC) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant * Systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors * Post-transplant treatment with mTOR inhibitors * Acute and unexpected medical contraindications * Pregnancy * Cold storage time of \> 10 hours (both study arms)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC Liver transplantation Oncological outcomes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    37 sites in 17 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ASST Grande Ospedale Metropolitano Niguarda (Milan)

    NOT_YET_RECRUITING

    Milan, 20162, Italy

  • Centro Hepato-Bilio-Pancreático e de Transplantação (CHBPT)

    NOT_YET_RECRUITING

    Lisbon, 1069-166, Portugal

  • Clarunis - University Digestive Health Care

    NOT_YET_RECRUITING

    Basel, Canton of Basel-City, 4031, Switzerland

  • Cleveland Clinic

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Copenhagen University Hospital

    RECRUITING

    Copenhagen, 2100, Denmark

  • Department of Surgical Oncology, Transplant Surgery and General Surgery, Medical University of Gdańsk

    RECRUITING

    Gdansk, 80-210, Poland

  • Freeman Hospital (Newcastle)

    NOT_YET_RECRUITING

    Newcastle, NE7 7DN, United Kingdom

  • Gemelli University Hospital

    NOT_YET_RECRUITING

    Rome, 00168, Italy

  • Hannover Medical School

    NOT_YET_RECRUITING

    Hanover, 30626, Germany

  • Hôpital de la Croix-Rousse (Lyon)

    NOT_YET_RECRUITING

    Lyon, 69004, France

  • Hôpitaux universitaires de Genève

    RECRUITING

    Geneva, 1205, Switzerland

  • Institut de Recherche Expérimentale et Clinique (IREC) UCLouvain (Brussels)

    RECRUITING

    Woluwe-Saint-Lambert, 1200, Belgium

  • Institute for Clinical and Experimental Medicine (IKEM) (Prague)

    RECRUITING

    Prague, 14021, Czechia

  • Karolinska Institutet (Stockholm)

    RECRUITING

    Stockholm, 17177, Sweden

  • King's College Hospital (London)

    NOT_YET_RECRUITING

    London, SE5 9RS, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    NOT_YET_RECRUITING

    Leeds, LS97TF, United Kingdom

  • Lithuanian University of Health Sciences

    NOT_YET_RECRUITING

    Kaunas, 50009, Lithuania

  • Medical University of Innsbruck

    RECRUITING

    Innsbruck, 6020, Austria

  • Medical University of Vienna

    RECRUITING

    Vienna, 1090, Austria

  • Medical University of Warsaw

    NOT_YET_RECRUITING

    Warsaw, 02-097, Poland

  • Milano Institutio Nazionale dei Tumori (Milan)

    NOT_YET_RECRUITING

    Milan, 20133, Italy

  • Oslo University Hospital

    NOT_YET_RECRUITING

    Oslo, 0450, Norway

  • Padova University Hospital

    NOT_YET_RECRUITING

    Padova, 35128, Italy

  • Rutgers New Jersey Medical School (New York)

    NOT_YET_RECRUITING

    New York, New York, 07103, United States

  • The Royal Free Hospital (London)

    NOT_YET_RECRUITING

    London, NW3 2QG, United Kingdom

  • University Hospital Zurich

    NOT_YET_RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

  • University Hospitals Birmingham

    NOT_YET_RECRUITING

    Birmingham, B15 2GW, United Kingdom

  • University Hospitals Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • University Medical Centre Hamburg-Eppendorf

    NOT_YET_RECRUITING

    Hamburg-Eppendorf, 20246, Germany

  • University Medical Centre Rotterdam - Erasmus University Medical Center

    NOT_YET_RECRUITING

    Rotterdam, 3015, Netherlands

  • University of Groningen and University Medical Centre Groningen

    NOT_YET_RECRUITING

    Groningen, 9713, Netherlands

  • University of Heidelberg

    NOT_YET_RECRUITING

    Heidelberg, 69120, Germany

  • University of Mainz

    NOT_YET_RECRUITING

    Mainz, 55131, Germany

  • University of Munich Grosshadern

    NOT_YET_RECRUITING

    München, 81377, Germany

  • University of Udine

    RECRUITING

    Udine, 33100, Italy

  • Universitätsklinikum Essen

    NOT_YET_RECRUITING

    Essen, 45122, Germany

  • Vall d'Hebron Barcelona Hospital Campus

    NOT_YET_RECRUITING

    Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.